Literature DB >> 21126718

Invasive meningococcal disease and travel.

Ziad A Memish1, Anette Goubeaud, Michael Bröker, Claudius Malerczyk, Atef M Shibl.   

Abstract

The epidemiology of invasive meningococcal disease varies geographically and in time and the risk of acquiring the disease varies regionally, as well as with living conditions and behavior. An area, in which meningococcal disease outbreaks have frequently occurred, is the "African meningitis belt", where epidemics of meningococcal disease with a peak incidence as high as 100-800/100,000 population/year have been reported. Another risk factor is mass gatherings including the Islamic pilgrimage to Makkah (Mecca), where outbreaks of meningococcal disease have repeatedly occurred. The latest outbreaks occurred during the Hajj pilgrimages of 2000 and 2001, when a shift from serogroup A disease to serogroup W135 occurred. Vaccination against serogroups A, C, W-135 and Y with novel conjugate vaccines may help protect individuals and reduce the spread of bacterial carriage and disease. Individuals who should be vaccinated include travelers to epidemic or hyperendemic areas (as identified by international health authorities), travelers for Umra or Hajj (Hajj pilgrims), travelers to high risk countries or regions (African meningitis belt) during the dry season or countries in sub-Saharan Africa outside the meningitis belt (where outbreak of meningitis has been reported in the preceding 2-3 years), military recruits or deployed military personnel, immunocompromized travelers and high school and college students. This review presents the global epidemiology of meningococcal disease, and discusses prophylaxis options including meningococcal ACWY vaccines.
Copyright © 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21126718     DOI: 10.1016/j.jiph.2010.09.008

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  16 in total

Review 1.  Safety of hepatitis B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy: a systematic review.

Authors:  Marinos C Makris; Konstantinos A Polyzos; Michael N Mavros; Stavros Athanasiou; Petros I Rafailidis; Matthew E Falagas
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

Review 2.  Review of meningococcal vaccines with updates on immunization in adults.

Authors:  Yorgo C Zahlanie; Moza M Hammadi; Soha T Ghanem; Ghassan S Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2014-02-05       Impact factor: 3.452

3.  Acquisition of meningococcal serogroup W-135 carriage in Turkish Hajj pilgrims who had received the quadrivalent meningococcal polysaccharide vaccine.

Authors:  M Ceyhan; M Celik; E T Demir; V Gurbuz; A E Aycan; S Unal
Journal:  Clin Vaccine Immunol       Date:  2012-11-07

4.  The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study.

Authors:  Ghassan Dbaibo; Noel Macalalad; Mari Rose Aplasca-De Los Reyes; Efren Dimaano; Veronique Bianco; Yaela Baine; Jacqueline Miller
Journal:  Hum Vaccin Immunother       Date:  2012-04-09       Impact factor: 3.452

5.  Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease.

Authors:  Michael Bröker; Brian Cooper; Lisa M Detora; Jeffrey J Stoddard
Journal:  Infect Drug Resist       Date:  2011-07-22       Impact factor: 4.003

6.  Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.

Authors:  Charissa Fay Corazon Borja-Tabora; Cecilia Montalban; Ziad A Memish; Dominique Boutriau; Devayani Kolhe; Jacqueline M Miller; Marie Van der Wielen
Journal:  BMC Infect Dis       Date:  2015-10-06       Impact factor: 3.090

7.  Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.

Authors:  Charissa Borja-Tabora; Cecilia Montalban; Ziad A Memish; Marie Van der Wielen; Veronique Bianco; Dominique Boutriau; Jacqueline Miller
Journal:  BMC Infect Dis       Date:  2013-03-05       Impact factor: 3.090

8.  Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.

Authors:  Ghassan Dbaibo; Nabil El-Ayoubi; Soha Ghanem; Farah Hajar; Veronique Bianco; Jacqueline M Miller; Narcisa Mesaros
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

9.  The Burden of Infant Meningococcal Disease in the United States.

Authors:  R Judelsohn; G S Marshall
Journal:  J Pediatric Infect Dis Soc       Date:  2012-03-01       Impact factor: 3.164

10.  Epidemiological and Molecular Characterization of Invasive Meningococcal Disease in Italy, 2008/09-2012/13.

Authors:  Arianna Neri; Patrizio Pezzotti; Cecilia Fazio; Paola Vacca; Fortunato Paolo D'Ancona; Maria Grazia Caporali; Paola Stefanelli
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.